RE:RE:RE:Buy Out Leading pharmaceutical expert for therapeutics in regenerative medicine strengthens the Sernova team in corporate development and strategic planning
LONDON, ONTARIO, July 16, 2020 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FWB: PSH), a regenerative medicine company specializing in clinical trials, announced today that an international advisory board has been established and Dr. Anke M. Schulte will be a member of this advisory board. Dr. Schulte is an internationally renowned expert in diabetes, cell therapy and regenerative medicine and has been with SANOFI, a leading international pharmaceutical company, for 19 years.
The members of Sernova's international advisory board (Global Advisory Board) provide their expertise and strategic know-how to support the ongoing development and future commercialization of Sernova's novel platform for therapeutics in regenerative medicine and cell therapy. They are also available to advise the company on clinical development programs, expansion plans, acquisitions of additional technologies, and collaborations and partnerships in the pharmaceutical sector.
But 2.87 shouldn't be an issue.